Retrospective assessment of tolerability and efficacy of zoledronate in the palliative treatment of cancer-bearing dogs

Zoledronate is a bisphosphonate frequently used for the treatment of hypercalcaemia of malignancy and tumour-associated bone pain in dogs, however, there is a paucity of information regarding its use in veterinary medicine. The aim of this retrospective study was to report the tolerability of zoledronate in the palliative treatment of cancer-bearing dogs and secondarily to to assess the efficacy of zoledronate for the treatment of hypercalcaemia of malignancy. Thirty-seven dogs (22 with tumour-associated bone pain and 15 with hypercalcaemia of malignancy) that received 114 zoledronate infusions were included. Tolerability was assessed by the absence of post-zoledronate hypocalcaemia or other adverse events as defined by Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events criteria. Efficacy was assessed by comparison of available ionized calcium levels before and after zoledronate administration in hypercalcaemic dogs. In 79% of zoledronate infusions, no adverse events were reported. The majority of adverse events which occurred in the other 21% of infusions could be attributed to concurrent chemotherapy or the underlying neoplastic disease. There was a small but significant increase in creatinine following treatment with zoledronate, however, none of the dogs developed clinically significant renal disease. In eight hypercalcaemic dogs with available ionized calcium following zoledronate administration, ionized calcium decreased rapidly within 7 days following treatment with zoledronate. Zoledronate is well-tolerated with few recorded adverse events, however, monitoring of serum creatinine is advised. Zoledronate seems to be effective in the treatment of hypercalcaemia of malignancy.     

PA-X基因的长度变化对H3N2犬流感病毒复制能力和致病性的影响

H3N2犬流感病毒(canine influenza virus, CIV)已在中国多地的犬群中流行,是禽流感跨宿主感染并形成新分支的近期案例。研究表明,PA-X基因与甲型流感病毒适应新宿主的能力相关,且其长度能够影响甲型流感病毒的复制及致病能力。为了解PA-X基因的长度变化对H3N2 CIV复制能力及致病力的影响,本研究利用H3N2 CIV的8质粒操作系统,拯救了三株重组H3N2 CIV毒株：PA-X基因表达大小为232个氨基酸多肽的亲本病毒CIV＿PA-X＿232;对PA编码区第191、192位氨基酸的密码子进行改造,PA-X基因不表达蛋白的重组病毒CIV＿PA-X＿Knock;对PA+1编码区第232位氨基酸进行突变,PA-X基因表达大小为252个氨基酸多肽的重组病毒CIV＿PA-X＿252。通过比较3株重组病毒的聚合酶活性,在MDCK细胞中的复制效率及对小鼠致病性的差异,来评价表达不同长度的PA-X基因对H3N2 CIV的影响。结果显示,CIV＿PA-X＿252和CIV＿PA-X＿Knock的聚合酶活性显著(P<0.05)高于CIV＿PA-X＿232,且CIV＿PA-X＿...     

犬瘟热病毒Lederle株H,N全基因序列分析及表达研究

采用RT-PCR方法自犬瘟热病毒Lederle株基因组RNA中扩增出H基因(1 911 bp)和N基因(1 707 bp)片段,序列测定和分析表明与Onderstepoort株、CDV3株等疫苗毒株的同源性在95%以上,而与野外分离株的同源性介于90%～95%;以获得的H,N全基因片段为模板,分别扩增H基因近3′端996 bp的基因片段以及N基因中间高度保守区562 bp的基因片段,经克隆测序后分别插入原核表达载体pET-32a中进行表达,结果显示H片段和N片段分别表达大小约为57 kD和37 kD的融合蛋白,Western blotting检测结果显示,表达蛋白均可与CDV抗血清发生阳性反应,提示原核表达产物具有与CDV抗血清结合的免疫反应性。     

肉桂醛、柠檬醛对犬白色念珠菌黏附力及超微结构的影响

根据先前的研究,肉桂醛和柠檬醛都有较好的抗真菌活性。本研究对肉桂醛、柠檬醛在真菌黏附口腔黏膜上皮以及对犬白色念珠菌超微结构的影响进行探索。结果表明,药物处理组白色念珠菌黏附率显著下降。扫描电镜显示,经过药物处理的犬白色念珠菌细胞表面粗糙、皱缩、萎陷、外膜空洞、胞浆内容物流出。透射电镜下,细胞普遍发生细胞壁增厚,质壁分离,萎陷,胞浆内容物外流等损伤。     

犬瘟热病毒F蛋白分子生物学研究进展

犬瘟热病毒融合蛋白是囊膜糖蛋白,是产生中和抗体的主要保护性抗原,结构相对保守。融合蛋白介导病毒囊膜和细胞膜融合,决定病毒在宿主体内扩散的能力,在病毒的致病性及免疫原性上具有重要作用。因此,对犬瘟热融合蛋白基因及其蛋白的结构和功能进行研究具有重要的意义。本文从蛋白结构、蛋白功能、核酸序列比对等多方面对融合蛋白进行了阐述。     

犬细小病毒病的临床诊疗效果研究

犬细小病毒病是由犬细小病毒（cpv）引起的一种急性传染病，发病率和死亡率比较高，达10％～50％，自愈率〈5％．笔者在近一年中的犬病治疗过程中用犬细小病毒快速诊断试纸条确诊为犬细小病毒病的有16例。经过临床治疗得出，除了采用高免血清和对症治疗外，治愈率的高低在很大程度上取决于输液，此外对病犬的护理正确精细与否也有一定的关系。本文重点介绍了犬细小病毒病的临床症状、剖检变化、鉴别诊断、治疗情况及治疗体会。     

毛皮动物犬瘟热、细小病毒性肠炎和脑炎防治技术指南

为了预防、控制和消灭毛皮动物犬瘟热、细小病毒性肠炎和脑炎,依据《中华人民共和国动物防疫法》及有关法律法规,制定毛皮动物犬瘟热、细小病毒性肠炎和脑炎防治技术指南,指导毛皮动物犬瘟热、细小病毒性肠炎和脑炎防控。